标题
E3 ligase ligand optimization of Clinical PROTACs
作者
关键词
-
出版物
Frontiers in Chemistry
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-01-17
DOI
10.3389/fchem.2023.1098331
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
- (2022) Xin Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
- (2022) Nathaniel J. Henning et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Prostate cancer
- (2021) Richard J. Rebello et al. Nature Reviews Disease Primers
- DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
- (2021) Xiaoyu Zhang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
- (2021) Haibin Zhou et al. ACS Medicinal Chemistry Letters
- Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
- (2021) Carmen Criscitiello et al. Anti-Cancer Agents in Medicinal Chemistry
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
- (2021) Jieli Wei et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- BRD9 Bifunctional Degraders for Treating Cancer
- (2021) Ram W. Sabnis ACS Medicinal Chemistry Letters
- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
- (2020) Thomas L. Gonzalez et al. BREAST CANCER RESEARCH AND TREATMENT
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia
- (2020) Ichiro Kawahata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics
- (2020) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear Localization and Exacerbates Atherosclerosis
- (2020) Mingming Liu et al. Cell Reports
- Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
- (2020) Liqun Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bardoxolone conjugation enables targeted protein degradation of BRD4
- (2020) Bingqi Tong et al. Scientific Reports
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- First targeted protein degrader hits the clinic
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- (2019) Carl C. Ward et al. ACS Chemical Biology
- Targeted protein degradation: elements of PROTAC design
- (2019) Stacey-Lynn Paiva et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- RNF4 – A Paradigm for SUMOylation‐Mediated Ubiquitination
- (2019) Ramesh Kumar et al. PROTEOMICS
- PROTAC Degradation of IRAK4 for the Treatment of Neurodegenerative and Cardiovascular Diseases
- (2019) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Cellular quality control by the ubiquitin-proteasome system and autophagy
- (2019) Christian Pohl et al. SCIENCE
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth
- (2019) Chimera Lyle et al. Scientific Reports
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- The role of STAT3 in leading the crosstalk between human cancers and the immune system
- (2018) Yu Wang et al. CANCER LETTERS
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
- (2018) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
- (2018) Taavi Neklesa et al. CANCER RESEARCH
- A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
- (2018) Brittany C. Michel et al. NATURE CELL BIOLOGY
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells
- (2018) Jovylyn Gatchalian et al. Nature Communications
- The Role of MDM2 in Promoting Genome Stability versus Instability
- (2017) M. Saadatzadeh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- In VivoKnockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
- (2017) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications
- (2017) Jean-Francois Arnal et al. PHYSIOLOGICAL REVIEWS
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
- (2016) Anja F Hohmann et al. Nature Chemical Biology
- Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
- (2016) Ying Jin et al. Scientific Reports
- Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
- (2015) Natalie H. Theodoulou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer
- (2014) Bo Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth
- (2014) Kimberly H. Kim et al. Cancer Genetics
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Toll-Like Receptor Signaling
- (2013) K.-H. Lim et al. Cold Spring Harbor Perspectives in Biology
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- Development of target protein-selective degradation inducer for protein knockdown
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells
- (2010) X T Zhang et al. ONCOGENE
- Building ubiquitin chains: E2 enzymes at work
- (2009) Yihong Ye et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways
- (2009) Brenda A. Schulman et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Demonstration of direct binding of cIAP1 degradation-promoting bestatin analogs to BIR3 domain: Synthesis and application of fluorescent bestatin ester analogs
- (2008) Shinichi Sato et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Signalling mechanisms for Toll-like receptor-activated neutrophil exocytosis: key roles for interleukin-1-receptor-associated kinase-4 and phosphatidylinositol 3-kinase but not Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFN-β (TRIF)
- (2008) Agnieszka A. Brzezinska et al. IMMUNOLOGY
- Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
- (2008) A Rodriguez-Gonzalez et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now